

# Animal and Translational Models for CNS Drug Discovery

VOLUME 3

## Reward Deficit Disorders



EDITED BY Robert A. McArthur • Franco Borsini



# Animal and Translational Models for CNS Drug Discovery

Animal and Translational Models for CNS Drug Discovery

*Volume I Psychiatric Disorders* (ISBN: 978-0-12-373856-1)

*Volume II Neurological Disorders* (ISBN: 978-0-12-373855-4)

*Volume III Reward Deficit Disorders* (ISBN: 978-0-12-373860-8)

(ISBN set: 978-0-12-373861-5)

# Animal and Translational Models for CNS Drug Discovery

**VOLUME III**  
Reward Deficit Disorders

**Edited by**

**Robert A. McArthur, PhD**

Associate Professor of Research  
Consultant Behavioral Pharmacologist  
McArthur and Associates GmbH, Basel, Switzerland

**Franco Borsini, PhD**

Head, Central & Peripheral Nervous System and  
General Pharmacology Area – R&D Department  
sigma-tau S.p.A., Pomezia (Rome), Italy



AMSTERDAM • BOSTON • HEIDELBERG • LONDON • NEW YORK • OXFORD  
PARIS • SAN DIEGO • SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO

Academic Press is an imprint of Elsevier



Academic Press is an imprint of Elsevier  
30 Corporate Drive, Suite 400, Burlington, MA 01803, USA  
360 Park Avenue South, New York, NY 10010-1710, USA  
525 B Street, Suite 1900, San Diego, CA 92101-4495, USA  
32 Jamestown Road, London NW1 7BY, UK

⊗ This book is printed on acid-free paper.

Copyright © 2008, Elsevier Inc. All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher.

Permissions may be sought directly from Elsevier's Science & Technology Rights Department in Oxford, UK: phone: (+44) 1865 843830, fax: (+44) 1865 853333, E-mail: [permissions@elsevier.com](mailto:permissions@elsevier.com). You may also complete your request online via the Elsevier homepage (<http://elsevier.com>), by selecting "Support & Contact" then "Copyright and Permission" and then "Obtaining Permissions."

#### **Library of Congress Cataloging-in-Publication Data**

A catalog record for this book is available from the Library of Congress.

#### **British Library Cataloguing-in-Publication Data**

A catalogue record for this book is available from the British Library.

ISBN: 978-0-12-373861-5 (set)

ISBN: 978-0-12-373860-8 (vol 3)

For information on all Academic Press publications  
visit our web site at [www.elsevierdirect.com](http://www.elsevierdirect.com)

Typeset by Charon Tec Ltd., A Macmillan Company.  
([www.macmillansolutions.com](http://www.macmillansolutions.com))

Printed and bound in the United States of America  
08 09 10 11 12 10 9 8 7 6 5 4 3 2 1

Working together to grow  
libraries in developing countries

[www.elsevier.com](http://www.elsevier.com) | [www.bookaid.org](http://www.bookaid.org) | [www.sabre.org](http://www.sabre.org)

ELSEVIER

BOOK AID  
International

Sabre Foundation

This book is dedicated to that happy band of behavioral pharmacologists who over the generations have occasionally seen their compound progress into clinical development, and more rarely still seen it used to treat patients. New skills are being learned and new species creeping into the lab, including the ones “without tails.” These offer new opportunities and challenges, but equally so greater satisfaction working at the interface. May all your compounds be winners!

This page intentionally left blank

# Contents

Preface ..... xv

Acknowledgements..... xxxix

List of Contributors ..... xli

## Volume 3 Animal and Translational Models for CNS Drug Discovery: Reward Deficit Disorders

**CHAPTER 1    Impulse and Reward Deficit Disorders:  
Drug Discovery and Development ..... 1**

Christian Heidbreder

Introduction.....2

The Key Messages of Epidemiology:What should be  
Modeled? .....2

    Drug Addiction .....3

    Behavioral Addictions.....3

Comorbid Associations.....5

From Epidemiology to Unmet Medical Needs to Drug  
Discovery and Development .....7

Challenges Facing Drug Discovery and Development in  
Impulse and Reward Deficit Disorders .....8

Toward Translational Value of Animal Models In Impulse  
and Reward Deficit Disorders.....10

    Key Neurosystems Relevant to Drug Discovery and  
    Development.....10

    Key Experimental Paradigms with Translational Potential for  
    Drug Discovery and Development.....11

    Compulsive/Impulsive Behaviors.....13

Target Validation and Throughput Limitations .....14

Target Validation, Validity, Reliability, and Automation .....15

Conclusions .....15

References.....16

  

**CHAPTER 2    Drug Discovery and Development for Reward  
Disorders: Views from Government ..... 23**

David J. McCann, Jane B. Acri and Frank J. Vocci

Introduction and Contextual Issues.....23

Division of Pharmacotherapies and Medical Consequences  
of Drug Abuse .....24

    Drug Discovery Program – Initial Operations.....24

    Drug Discovery Program – Current Status.....26



Development of Medications for Opiate and Cocaine  
Addiction .....27

Animal Models In The Discovery Of Drug Addiction Treatments .....30

The Validity of Animal Models in the Field of Drug Addiction .....30

Use of Data from Animal Models for “Go/No Go” Decisions .....30

Avoiding False Positives in Drug Self-administration and  
Relapse Model Testing ..... 31

Translational Research, Human Laboratory Models, and the Bridge  
between Animal Models and Clinical Efficacy Trials .....34

References.....38

**CHAPTER 3      Issues in Designing and Conducting Clinical Trials  
for Reward Disorders: A Clinical View.....41**

Tracie J. Gardner, Therese A. Kosten and  
Thomas R. Kosten

Introduction.....41

Utility of Research using Animal Models.....42

Advantages of Animal Research .....42

Drug Exposure .....42

Behavioral Techniques in Animal Research .....43

Drug Self-administration.....44

Human Testing Paradigms for New Medications.....45

Human Laboratory .....45

Self-administration.....46

Neuroimaging .....46

Methodological Issues in Clinical Trials .....47

Target Population and Subject Selection .....47

General Design Issues .....49

Statistical Issues.....51

Conclusions .....52

Acknowledgments .....53

References.....53

**CHAPTER 4      The Role of Animal Models in Reward Deficit  
Disorders: Views from Academia .....59**

George F. Koob

Introduction and Definitions .....60

Face and Construct Validity of Animal Models of Reward  
Deficits In Psychiatric Illness .....61

Face Validity and Construct Validity of Animal Models of  
Reward Deficits in Psychiatric Disorders.....62

Brain Stimulation Reward.....62

Sucrose Consumption/Sucrose Preference .....65

Progressive-Ratio Responding .....65

Drug Withdrawal Model of Dependence .....	66
Brain Stimulation Reward As a Measure of the Reward Deficits	
Associated with Drug Dependence.....	67
Sucrose Intake/Preference As a Measure of the Reward Deficits	
Associated with Drug Dependence.....	67
Progressive-Ratio Responding As a Measure of Reward Deficits	
Associated with Drug Dependence.....	68
Chronic Mild Stress and Depression.....	70
Brain Stimulation Reward As a Measure of the Reward Deficits	
Associated with the Chronic Mild Stress Model of Depression.....	70
Sucrose Intake/Preference As a Measure of the Reward Deficits	
Associated with the Chronic Mild Stress Model of Depression.....	71
Progressive-Ratio Responding as a Measure of the Reward Deficits	
Associated with the Chronic Mild Stress Model of Depression.....	75
Validity of Animal Models of Reward Deficits .....	75
Common Neurobiological Substrates for the Reward Deficits	
in Addiction and Depression.....	76
Neurochemical Substrates in Dependence .....	76
Neurochemical Substrates in Depression .....	77
Extended Amygdala .....	78
Allostasis in Reward Function .....	79
Translational Value of these Models and Procedures for	
the Study of Reward Deficits in Man.....	80
Prospects for the Development of New Therapeutics of	
Reward Deficit Disorders.....	81
Summary and Conclusions.....	81
Acknowledgments .....	82
References.....	82

<b>CHAPTER 5</b>	<b>Pharmacotherapy of Alcohol Dependence: Improving Translation from the Bench to the Clinic .....</b>	<b>91</b>
	Hilary J. Little, David L. McKinzie, Beatrice Setnik, Megan J. Shram and Edward M. Sellers	
	Introduction.....	92
	Epidemiology/Clinical and Societal Impact .....	92
	Types of Alcoholism.....	94
	Diagnostic Features of Alcohol Dependence .....	95
	Clinical Diagnostic Criteria for Alcohol Dependence and their Importance in the Development of Animal Models .....	96
	Important Non-diagnostic Components of Alcohol Dependence.....	99
	Current Treatment of Alcohol Dependence .....	102
	Human Pharmacology and Experimental Medicine Approaches	
	to the Treatment of Alcohol Dependence .....	107
	Review of Clinical Trial Design.....	107

Behavioral Models of Alcohol Dependence .....	109
Voluntary Drinking Choice Model.....	109
Forced Alcohol Consumption .....	117
Effects of Clinically Effective and Novel Drugs on Alcohol Withdrawal .....	117
Alcohol Place Conditioning.....	118
Changes in Alcohol Place Conditioning After Chronic Treatment and Reinstatement of Conditioned Place Preference.....	120
Effects of Aversive Consequences on Alcohol Place Conditioning .....	120
Effects of Clinically Effective and Novel Drugs on Alcohol Place Conditioning.....	121
Family History of Alcohol Dependence.....	132
Genes Associated with Risk of Alcohol Dependence .....	134
Correspondence of Efficacy of Established and Novel Treatments for Alcohol Dependence in Animals and Humans.....	141
Consensus Statement Regarding Animal Models of Alcohol Dependence.....	142
References.....	144

## **CHAPTER 6      Contribution of Animal Models and Preclinical Human Studies to Medication: Development for Nicotine Dependence..... 179**

Athina Markou, Christian V. Chiamulera and Robert J. West	
Introduction.....	180
The Problem of Tobacco Smoking.....	180
Tobacco Addiction and Nicotine Dependence.....	180
Criteria for Defining Nicotine Dependence in Humans.....	184
Animal Models of Nicotine Dependence.....	185
What is a Model?.....	185
Models of Various Aspects of Nicotine Withdrawal .....	188
Models of Reinstatement of Nicotine-Seeking Behavior with Relevance to Relapse .....	189
Animal Models of Motivation for Nicotine .....	190
Historical Background: Why Drug Discovery on Nicotine Dependence Was Different from that on Other Drugs of Abuse.....	191
Preclinical Animal Models of Nicotine Dependence in Drug Discovery .....	193
Limitations of Drug Discovery Assays and Models for Nicotine Dependence .....	196
Human Preclinical and Clinical Studies .....	199
Ad Libitum Smoking Studies.....	200
Studies of Withdrawal Symptoms and “Craving” During Abstinence .....	201
Short-Term Abstinence Studies.....	202
Small-Scale Open-Label Studies .....	203
Commentary .....	203

Successes, Failures and Serendipity in Translational Research .....	204
Challenges, Opportunities, and Perspectives .....	205
Translational Medicine: from Mechanism of Action to	
Clinical Efficacy .....	205
Product Profile and Return-of-Research-Investment .....	206
Experimental Medicine Paradigm Shift and Translational	
Research .....	206
Acknowledgements .....	207
References .....	207

## **CHAPTER 7      Development of Medications for Heroin and Cocaine Addiction and Regulatory Aspects of Abuse Liability Testing ..... 221**

Beatriz A. Rocha, Jack Bergman, Sandra D. Comer, Margaret Haney and Roger D. Spealman	
Introduction .....	222
Opioid and Cocaine Addiction .....	225
Pharmacotherapy for Drug Addiction and Abuse Potential of	
New Compounds .....	228
Animal Laboratory Models .....	228
Human Laboratory Models .....	237
Assessment of Abuse Liability of Compounds: the Regulatory	
Environment .....	242
Regulatory Environment in the United States and the EU .....	242
World Health Organization .....	244
Approved and Proposed Medications to Treat Opioid and	
Cocaine Addiction .....	245
Heroin (Opioid) Addiction .....	245
Cocaine Addiction .....	249
Concordance Between Animal and Human Laboratory Studies and	
Clinical Outcome .....	254
Improving the Predictive Value of Existing Models .....	255
Improving the Predictive Value of Existing Models in the	
Assessment of Abuse Liability .....	257
References .....	258

## **CHAPTER 8      Anti-obesity Drugs: From Animal Models to Clinical Efficacy ..... 271**

Colin T. Dourish, John P.H. Wilding and Jason C.G. Halford	
Introduction .....	272
Clinical Aspects of Obesity and Cardiometabolic Disease .....	273
Background - Do We Need Drugs for Obesity? .....	273
Current Drugs for Obesity and Their Limitations .....	274

Other Drugs - Withdrawn or No Longer Recommended for Routine Clinical Use.....	275
The Need for New Drugs .....	275
Biology and Genetics of Energy Regulation and Implications for Obesity .....	276
Short-Term (Episodic) Signals .....	276
Long-Term (Tonic) Signals.....	278
CNS Integrating Pathways .....	279
Biomarkers of Energy Regulation and Obesity .....	280
Anthropometric Measures.....	280
Measures of Adiposity.....	281
Measures of Energy Expenditure .....	281
Risk Factors.....	282
Insulin Resistance and Systemic Inflammation .....	282
The Psychobiology of Appetite Expression .....	283
Episodic Signals in the Regulation of Appetite Expression .....	283
Tonic Signals in the Regulation of Appetite Expression .....	283
Psychological and Behavioral Aspects of Obesity .....	283
Genetics Versus Environment? .....	284
Obese Eating Style? .....	284
Trait Hunger, Disinhibition, and Binge Eating .....	286
Behavioral Indices for Assessing the Action and Efficacy of Anti-obesity Drugs.....	287
Susceptibility to Obesity and Hyperphagia.....	287
Structure of Feeding Behavior.....	288
Assessing the Effects of Drugs on Human Feeding Behavior .....	288
Microstructure of Human Eating Behavior: Eating Rate, Cumulative Intake Curves and Deceleration.....	289
Molecular Targets for Anti-obesity Drugs.....	290
Lipase Inhibitors.....	290
Serotonin/Noradrenaline Reuptake Inhibitors.....	291
Selective Serotonin Receptor Ligands .....	292
Cannabinoid Receptor Ligands .....	295
Neuropeptide Receptor Ligands .....	295
Screening Strategies from Molecular Target to Initial Clinical Trial .....	297
Proof of Concept for Novel Anti-obesity Drugs: The Role of Experimental Medicine Studies to Determine Drug Efficacy and Side-effects .....	299
Measurement of Anti-Obesity Drug Efficacy in Experimental Medicine Studies: The UEM Approach .....	299
Measurement of Anti-Obesity Drug Efficacy and CNS Side-Effects in Experimental Medicine Studies: The Emotional Test Battery Approach .....	300
Summary .....	302
References.....	302

<b>CHAPTER 9</b>	<b>Current Concepts in the Classification, Treatment and Modeling of Pathological Gambling and Other Impulse Control Disorders .....</b>	<b>317</b>
	Wendol A. Williams, Jon E. Grant, Catharine A. Winstanley and Marc N. Potenza	
	Introduction .....	318
	Neurobiology of Pathological Gambling.....	319
	Biochemistry of Neurotransmitters.....	319
	Stress Response Systems .....	322
	Opioidergic Pathways .....	323
	Neuroimaging .....	324
	Genetic Considerations.....	325
	Conclusions.....	326
	Treatment.....	326
	Pathological Gambling .....	326
	Trichotillomania.....	331
	Compulsive Buying/Shopping.....	333
	Intermittent Explosive Disorder .....	334
	Kleptomania.....	335
	Insight from Animal Models .....	337
	Animal Models of Gambling Behavior .....	337
	The Feasibility of Modeling Gambling in Animals .....	338
	Considerations for a Model of Pathological Gambling .....	340
	Summary .....	342
	Conclusions and Recommendations.....	342
	References.....	343
<b>EPILOGUE</b>	<b>Translational Models for the 21st Century: Reminiscence, Reflections and Some Recommendations .....</b>	<b>359</b>
	Paul Willner, Franco Borsini and Robert A. McArthur	
	Introduction.....	359
	References.....	369
	Index .....	377

This page intentionally left blank

# What Do *You* Mean by “Translational Research”? An Enquiry Through Animal and Translational Models for CNS Drug Discovery: Reward Deficit Disorders

**Robert A. McArthur<sup>1</sup> and Franco Borsini<sup>2</sup>**

<sup>1</sup>McArthur and Associates GmbH, Basel, Switzerland

<sup>2</sup>sigma-tau S.p.A., Pomezia (Rome), Italy

In the 50-odd years since the introduction of clinically effective medications for the treatment of behavioral disorders such as depression,<sup>1</sup> anxiety<sup>2</sup> or schizophrenia<sup>3</sup> there has recently been growing unease with a seeming lack of substantive progress in the development of truly innovative and effective drugs for behavioral disorders; an unease indicated by escalating research and development expenditure associated with diminishing returns (e.g.,<sup>4</sup> and discussed by Hunter<sup>5</sup> in this book series). There are a number of reasons that may account for this lack of new drugs for CNS disorders (cf.,<sup>6</sup>), but according to the US Food and Drug Administration's (FDA) white paper on prospects for 21st century drug discovery and development,<sup>7</sup> one of the main causes for failure in the clinic is the discrepancy between positive outcomes of candidate drugs in animal models and apparent lack of efficacy in humans, that is, the predictive validity of animal models. Consequently, there have been a number of initiatives from the US National Institutes of Health (NIH) (<http://nihroadmap.nih.gov/>) and The European Medicines Agency (EMA)<sup>8</sup> to bring interested parties from Academia and Industry together to discuss, examine and suggest ways of improving animal models of behavioral disorders.<sup>9-14</sup> The value of NIH-supported initiatives, even to the point of participating directly in drug discovery from screening to registration is not to be underestimated, as evidenced by the successful registration of buprenorphine (Subutex®) and buprenorphine/naloxone (Suboxone®) by Reckitt-Benckiser in collaboration with the National Institute on Drug Abuse (NIDA)<sup>15</sup>, see also<sup>16,1</sup>

Translational research and experimental medicine are closely related activities that have evolved in answer to the need of improving the attrition rate of novel drugs between the preclinical and clinical stage of development.<sup>5,19-22</sup> In general, translational research defines the *process* through which information and insights flow from

<sup>1</sup> For a comprehensive discussion of NIH-sponsored initiatives and collaborations and opportunities, please refer to Winsky and colleagues<sup>17</sup> and Jones and colleagues<sup>18</sup> for specifics on NIH-Academic-Industrial collaborations in schizophrenia.



clinical observations to refine the development of animal models *as well as* the complementary flow of information and insights gained from animal models to the clinical setting, be it through improved diagnosis, disease management or treatment; including pharmacological treatment.<sup>23</sup> Experimental medicine, in terms of drug discovery, refers to studies in human volunteers to (1) obtain mechanistic and pharmacological information of compounds entering into development, (2) explore and define biological markers with which the state and progress of a disorder can be monitored, as well as the effects of pharmacological interventions on its progress and (3) establish models and procedures with which to obtain initial signals of efficacy test.<sup>5,15,22</sup> Though claimed as an innovative paradigm shift, translational research nevertheless, is not a new concept, as pointed out by Millan in this book series.<sup>24</sup> The origins of psychopharmacology abound with numerous examples of how pharmaceutical or medicinal chemists interacted directly with their clinical colleagues to “test their white powder”, or clinicians who would knock at the chemists’ door for anything new. Kuhn and Domenjoz, for example, describes the initial “Phase II” trials of the novel “sleeping pill” forerunner of imipramine.<sup>25,26</sup> Paul Janssen tells how the observation of the paranoid schizophrenia-like hallucinations experienced by cyclists who were consuming amphetamine to stay alert, led him to search for better amphetamine antagonists, one of which was haloperidol. This compound was subsequently given to a young lad in the midst of a psychotic episode by a local psychiatrist with good results.<sup>27</sup> Though largely overtaken in sales and prescription rates by 2nd generation atypical antipsychotics, Haloperidol (Haldol®) remains one of the standard drugs used in the treatment of schizophrenia.<sup>18,28,29</sup>

Translational research is a two-way process which, nonetheless can lead to differences in emphasis and agenda. We have gathered a number of definitions from different sources listed in Table 1 below to help us determine what one of our authors asked us to do when he was contacted to contribute to this book project, “What do *you* mean by ‘translational research’?”

These definitions may emphasize the clinical, or top-down approach to translational research,<sup>20,30</sup> or the bottom-up approach of “bench-to-bedside”.<sup>21,31</sup> It is clear though, that translational research has a purpose of integrating basic and clinical research for the benefit of the patient in need. While we welcome this as a general definition of translational research, we acknowledge, as do others (e.g.,<sup>31,32</sup>), that a more pragmatic, working definition is required. Consequently, we define translational research, in the context of drug discovery and research, as the partnership between preclinical and clinical research to align not only “... basic science discoveries into medications”,<sup>31</sup> but also the information derived from the clinic during the development of those medications. The purpose of this reciprocal definition is to refine the model systems used to understand the disorder by identifying the right targets, interacting with those targets pharmacologically in both animals and humans and monitoring the responses in each throughout a compound’s development (cf.,<sup>5 and 15</sup>). Central to this definition is the acknowledgement that the etiology of behavioral disorders and their description are too diffuse to attempt to model or simulate in their entirety. Consequently, emphasis must be placed on identifying specific symptoms or core features of the disorder to model, and to define biological as well as behavioral responses as indices of state, changes in state and response to pharmacological treatment. This process is made easier if, at the same time, greater effort is made to identify procedures used to

**Table 1** Selected definitions of translational research

Definition	Reference
Translational medicine may also refer to the wider spectrum of patient-oriented research that embraces innovations in technology and biomedical devices as well as the study of new therapies in clinical trials. It also includes epidemiological and health outcomes research and behavioral studies that can be brought to the bedside or ambulatory setting.	30
...connotes an attempt to bring information that has been confined to the laboratory into the realm of clinical medicine.	
To the extent that clinical studies could be designed to answer such questions (generated by information from the laboratory), they would represent types of translational clinical research.	20
...a two-way street where the drive to cure should be complemented by the pursuit to understand human diseases and their complexities.	21, 162
1. Basic science studies which define the biological effects of therapeutics in humans	
2. Investigations in humans which define the biology of disease and provide the scientific foundation for development of new or improved therapies for human disease	
3. Non-human or non-clinical studies conducted with the intent to advance therapies to the clinic or to develop principles for application of therapeutics to human disease	
4. Any clinical trial of a therapy that was initiated based on #1–3 with any endpoint including toxicity and/or efficacy.	M. Sznol cited by <sup>21</sup>
...research efforts intended to apply advances in basic science to the clinical research setting. For drug discovery and development, the term refers to research intended to progress basic science discoveries into medications.	31
By bringing together top-down and bottom-up approaches, there is potential for a convergence of unifying explanatory constructs relating aetiology to brain dysfunction and treatment.	37, 163
...information gathered in animal studies can be translated into clinical relevance and vice versa, thus providing a conceptual basis for developing better drugs.	
...the application of scientific tools and method to drug discovery and development ... taking a pragmatic or operational rather than a definitional approach, a key to a successful translation of non-human research to human clinical trials lies in the choice of biomarkers.	32
...two-way communication between clinical and discovery scientists during the drug development process are likely to help in the development of more relevant, predictive preclinical models and biomarkers, and ultimately a better concordance between preclinical and clinical efficacy.	82

measure these biological and behavioral responses that are consistent within and between species.<sup>23,24</sup> Brain imaging is one technique that has cross-species consistency (e.g.,<sup>33-36</sup>), as do various operant conditioning procedures.<sup>37,38</sup>

There are at least two aspects of translational research to be considered as a result of the definition proposed above. First is the concept of specific symptoms, or core features of the disorder to model. Attempts to simulate core disturbances in behavior formed the basis of early models of behavioral disorders. McKinney and Bunney, for example, describe how they sought to “translate” the clinically observed changes in human depressed behavior (secondary symptoms) with analogous changes in animals induced by environmental or pharmacological manipulations.<sup>39</sup>

Whereas modelers have traditionally referred to diagnostic criteria such as DSM-IV<sup>40</sup> or ICD-10<sup>41</sup> the consensus to be found in this book series and other sources is that these diagnostic criteria do not lend themselves easily to basic or applied research. The etiology of behavioral disorders is unclear, and there is considerable heterogeneity between patients with different disorders but similar symptoms. Nevertheless, attempts to model particular behavioral patterns have been and are being done. Thus, for example, the construct of anhedonia (the loss of ability to derive pleasure), or the construct of social withdrawal, may be diagnostic criteria for a number of behavioral disorders including depression, schizophrenia, as well as a number of other disorders (cf.,<sup>42</sup>). There is considerable momentum to establish a dimension – rather than diagnostic-based classification or to “deconstruct” syndromes into “symptom-related clusters” that would help guide neurobiological research.<sup>ii 18,43,44</sup> In order to define these “symptom-based clusters”, however, the symptoms have to be defined. Previously, these were identified as behavioral patterns, though lately they have been referred to variously as behavioral endophenotypes or exophenotypes (e.g.,<sup>45-49</sup>). It is appropriate here to review the definitions of both. Exophenotype and endophenotypes have been defined by Gottesman and Schields<sup>50</sup> as:

*John and Lewis (1966) introduced the useful distinction between exophenotype (external phenotype) and endophenotype (internal), with the latter only knowable after aid to the naked eye, e.g. a biochemical test or a microscopic examination of chromosome morphology (p. 19).<sup>iii</sup>*

Subsequently, endophenotypes have been more rigorously defined<sup>51</sup> as:

1. *The endophenotype is associated with illness in the population.*
2. *The endophenotype is heritable.*
3. *The endophenotype is primarily state-independent (manifests in an individual whether or not illness is active).*
4. *Within families, endophenotype and illness co-segregate.*
5. *The endophenotype found in affected family members is found in nonaffected family members at a higher rate than in the general population. (p. 639)*

<sup>ii</sup> For reviews of the initiatives deconstructing a complex disorder like schizophrenia, the reader is invited to consult the following 2 issues of *Schizophrenia Bulletin*, where these initiatives are thoroughly discussed: *Schizophr Bull*, 2007, 33:1 and *Schizophr Bull*, 2007, 33:4.

<sup>iii</sup> See also Tannock *et al.*,<sup>61</sup> for definitions of endophenotypes and biomarkers.

And that "...The number of genes involved in a phenotype is theorized to be directly related to both the complexity of the phenotype and the difficulty of genetic analysis" (*op cit.*, p. 637). On the other hand, exophenotypes have been defined by Holzman<sup>52</sup> (and others) as:

*... the external symptoms of a disorder that clinicians detect during an examination. An endophenotype, on the other hand, is a characteristic that requires special tools, tests, or instruments for detection. (p. 300)*

It behooves the unwary researcher to be careful with terminology and thus not fall into the trap of pretending greater accuracy by changing the name of the phenomenon being studied. Finally, to quote Hyman's *caveat*<sup>43</sup>,

*The term "endophenotype" has become popular for describing putatively simpler or at least objectively measurable phenotypes, such as neuropsychological measures that might enhance diagnostic homogeneity. I find this term less than ideal, because it implies that the current diagnostic classification is basically correct, and that all that is lacking is objective markers for these disorders. If, however, the lumping and splitting of symptoms that gave rise to the current classification was in error, then the search for biological correlates of these disorders will not prove fruitful. (p. 729).*

The second aspect to be considered in translational research is the concept of biomarkers. Biomarkers are crucial to translational research and serve as the interface between preclinical research, experimental medicine and clinical development. As with endophenotypes above, however, biomarkers also require some discussion. The FDA, NIH and EMEA have been at the forefront in helping define and establish biomarkers, surrogate markers and clinical endpoints<sup>53-57</sup> (<http://ospp.od.nih.gov/biomarkers/>); an initiative now being carried out in partnership with private enterprise<sup>58</sup> (<http://ppp.od.nih.gov/pppinfo/examples.asp>). Lesko and Atkinson have provided summary definitions of various markers that are worth considering:<sup>55</sup>

*A synthesis of some proposed working definitions is as follows: (a) biological marker (biomarker) - a physical sign or laboratory measurement that occurs in association with a pathological process and that has putative diagnostic and/or prognostic utility; (b) surrogate endpoint - a biomarker that is intended to serve as a substitute for a clinically meaningful endpoint and is expected to predict the effect of a therapeutic intervention; and (c) clinical endpoint - a clinically meaningful measure of how a patient feels, functions, or survives. The hierarchical distinction between biomarkers and surrogate endpoints is intended to indicate that relatively few biomarkers will meet the stringent criteria that are needed for them to serve as reliable substitutes for clinical endpoints (p. 348).*

An important characteristic of biomarkers is that they should also be capable of monitoring disease progression.<sup>54</sup> It is interesting more over that the establishment of biomarkers should also be subject to the same concepts of validity as defined by Willner initially for models of behavioral disorders, that is, face, construct and predictive validity.<sup>59</sup> Lesko and Atkinson further indicate that biomarkers must be evaluated and validated for (1) clinical relevance (face validity in being able to reflect

physiologic/pathologic processes), (2) sensitivity and specificity (construct validity that it is capable to measure changes through a given mechanism in a target population) and (3) must ultimately be validated in terms of clinical change, that is, predictive validity. Biomarkers also have other criteria that they need to fulfill such as: their accuracy, precision and reproducibility; an estimated rate of false positive and false negative probability; and practicality and simplicity of use. In addition, pharmacological isomorphism is used to establish a biomarker's predictive validity where response to a known clinically effective standard is ultimately required, especially if drugs of different mechanisms of action produce the same response in the biomarker. These criteria are very familiar to the animal modeler and highlight the shared interests and expertise that the preclinical researcher brings to the clinical arena. Biomarkers for behavioral disorders thus share many of the problems inherent to their animal models.<sup>60</sup> Nevertheless, it is among the most active pursuits in Pharma today (cf.,<sup>61-70</sup>).

It is clear from the previous discussion that translational research demands the combined efforts of a number of participants, each of which contributes a particular expertise to achieve a common goal. Translational research cannot be done effectively using the “tried and true” process of compartmentalization prevalent up to the end of the last century, that is, the splitting of R from D, or maintaining the preclinical from clinical, academic from industrial divides. For the past decade Pharma has fostered cross-disciplinary collaboration with the creation of Project teams in which participants from preclinical, clinical and marketing sections of the Industry are brought together in relation to the maturity of the Project. The concept of “pitching the compound over the fence” is no longer tolerated, and preclinical participation even in mature Projects is expected. This creates a much more stimulating environment for all the participants, who not only learn from the experiences of others, but also maintain a sense of ownership even when their particular expertise is no longer required for a Project's core activities. Nevertheless, creation of and participation in Project teams is not always an easy task as group dynamics evolve. Team members are assigned to a Project by line managers, and can be removed depending on priorities. Some team members contribute more than their share, while others coast. The skills of the Project Leader must go beyond scientific expertise in order to forge an effective team and deliver a successful drug.

The use of animal models is an essential step in the drug discovery and indeed the translational research process. Use of appropriate models can minimize the number of drug candidates that later fail in human trials by accurately predicting the pharmacokinetic and dynamic (PK/PD) characteristics, efficacy and the toxicity of each compound. Selection of the appropriate models is critical to the process. Primary diseases such as those caused by infections, genetic disorders or cancers are less problematic to model using both *in vitro* and *in vivo* techniques. Similarly some aspects of degenerative diseases have also been successfully modeled. However, modeling of disorders with a strong behavioral component has been less successful. This is not to say that there are no models for various aspects of these disorders. Many models have been proposed, validated pharmacologically with standard, clinically effective drugs and extensively reviewed. Indeed, these models have become so standardized that their use to characterize mechanisms of action and lead novel compounds in CNS drug discovery projects is mandatory, and positive outcomes are required before these

compounds are considered for further development. However, it has become clear that positive outcome in these models is no guarantee that these new compounds will be efficacious medicines in humans. Refinements of existing models and development of new models relevant to drug discovery and clinical outcome are being pursued and documented (e.g.,<sup>71-74</sup>). Advancements in genetic aspects of disease are also being aided through the development and use of genetically modified animals as model systems. However, even though these techniques are more precise in modeling aspects of a disease such as amyloid overexpression in Alzheimer's disease, the ability of procedures used to assess the changes in behavior, and relating them to altered human behavior remains uncertain.

Books on animal models of psychiatric and neurological diseases have tended to be compendia of so-called "standard" procedures developed over the years. Some of these books have formed part of classic reference texts for behavioral pharmacologists (e.g.,<sup>75,76</sup>). Others – more pragmatic in their approach – describe the application of these models and are useful as "cookbook" manuals (e.g.,<sup>77,78</sup>), while yet others have been very specific in their focus; for example, books entirely with models for a particular disorder, for example, depression or schizophrenia. It could be argued, however, that these books address a very circumscribed audience, and need not be necessarily so. Clinicians might and do claim that animal models are intellectually interesting, but of no relevance to their daily work of (1) demonstrating proof of concept, (2) showing efficacy or (3) treating their patients. Nevertheless, clinicians are constantly on the watch for potentially new pharmacological treatments with which to treat their patients, for example, new chemical entities that have reached their notice following extensive profiling in animal models. Academics develop a number of procedures or models to help them study neural substrates and disorders of behavior, and may use pharmacological compounds as tools to dissect behavior. The industrial scientist is charged with the application of these methods and models, establishing them in the lab at the request of the Project team and Leader. There is thus a shared interest in the development, use and ability of animal models to reflect the state of a disorder and predict changes in state following pharmacological manipulation. This shared interest has generated much collaboration between academics, clinicians and the industry (cf.,<sup>79</sup>).

Paradoxically in view of shared interest, close ties and general agreement on the need for bidirectional communication, the integration of the perspective and experience of the participants in the drug discovery and development process is not always apparent and is a source of concern (e.g.,<sup>6,21,31,32,80-82</sup>). Although we do not necessarily agree entirely with Horrobin's description of biomedical research scientists as latter day Castalians,<sup>80</sup> we suggest that there is a certain truth to the allusion that considerable segregation between the academic, clinician and industrial researcher exists (see also<sup>21,81</sup>). There have been numerous attempts to break down these barriers, such as having parallel sessions at conferences, or disorder-specific workshops organized by leading academics, clinicians and industrial scientists (e.g., *op. cit.*,<sup>83</sup>). With few exceptions, however, academics will talk to academics, clinicians to clinicians and industrial scientists will talk to either academics or clinicians; depending on at which stage their Project is. Willner's influential book<sup>84</sup>, *Behavioral Models in Psychopharmacology: Theoretical, Industrial and Clinical Perspectives* represents one of the first published